4.7 Article

The citrulline generation test: proposal for a new enterocyte function test

Journal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 27, Issue 12, Pages 1300-1310

Publisher

WILEY
DOI: 10.1111/j.1365-2036.2008.03678.x

Keywords

-

Ask authors/readers for more resources

Background The amino acid citrulline is mainly produced by enterocytes from conversion of glutamine. As fasting plasma citrulline proved disappointing as a biomarker for enterocyte dysfunction in clinical practice, we propose a citrulline generation test (CGT) to assess enterocyte function. Aim To assess the feasibility of a CGT in healthy subjects and patients with decreased enterocyte mass. Methods Nineteen healthy subjects, 16 patients with intestinal villous atrophy and nine patients with short bowel syndrome (SBS) were given an oral bolus of 20 g of the dipeptide alanine-glutamine. Subsequent changes in plasma citrulline and other amino acid concentrations were determined using reverse-phase high-performance liquid chromatography. Results Following the oral bolus of alanine-glutamine, plasma citrulline concentrations showed a time dependent rise in healthy subjects of 44 +/- 13% (38-55 mu mol/L, P < 0.0001). The slope from baseline plasma citrulline to peak concentrations was 0.22 +/- 0.08, 0.13 +/- 0.04 and 0.09 +/- 0.04 mu mol/L/min in healthy subjects, patients with coeliac disease (CeD) and refractory CeD, respectively (healthy subjects vs. CeD P < 0.05, healthy subjects vs. refractory CeD P < 0.001). In patients with SBS, the CGT was able to distinguish between non-adapted and adapted SBS by means of the incremental area under the CGT curve till 90 min (iAUC T90). The iAUC T90 was 447 +/- 179 and 1039 +/- 178 mu mol/L/min in non-adapted and adapted SBS, respectively (P = 0.04). Conclusion An oral bolus of alanine-glutamine induces a time-dependent rise in plasma citrulline concentration to an extent dependent on the existence of villous atrophy or enterocyte hyperplasia in CeD, and adapted SBS, respectively.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Gastroenterology & Hepatology

Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

Tessa Straatmijer, Vince B. C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K. H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D. M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M. P. J. A. van der Voorn, Rachel West, Janneke van der Woude, Marije D. J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein

Summary: This study compared the effectiveness and safety of vedolizumab and tofacitinib in anti-TNF-exposed patients with UC. The results showed that tofacitinib was associated with superior effectiveness outcomes compared with vedolizumab, along with comparable safety outcomes.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry

Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein

Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease

Ashkan Rezazadeh Ardabili, Dirk van Esser, Dion Wintjens, Mia Cilissen, Debbie Deben, Zlatan Mujagic, Fritzi Russ, Laurents Stassen, Adriaan A. Van Bodegraven, Dennis Wong, Bjorn Winkens, Daisy Jonkers, Marielle Romberg-Camps, Marie J. Pierik

Summary: A remote monitoring tool, called the PRIQ, has been developed and validated to assess infections in IBD patients, enabling personalized medicine based on adequate benefit-risk assessments.

JOURNAL OF CROHNS & COLITIS (2023)

Article Pharmacology & Pharmacy

Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment-TUMMY Study

Merve Sivridas, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Romkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks

Summary: The aim of this study was to determine the association between vedolizumab (VDZ) trough concentration and clinical and biochemical remission in the maintenance phase. The results showed no statistically significant correlation between VDZ concentration and clinical remission in all patient groups. However, patients in biochemical remission had higher VDZ trough concentrations. Therefore, there is an association between VDZ concentration and biochemical remission, but not with clinical remission.

PHARMACEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses

Ashkan Rezazadeh Ardabili, Adriaan A. Van Bodegraven

Summary: This article is linked to the paper by Everhov et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors

L. M. Janssen, A. Rezazadeh Ardabili, M. J. L. Romberg-Camps, B. Winkens, R. J. van den Broek, J. Hulst, H. J. A. Verwijs, D. Keszthelyi, D. M. A. E. Jonkers, A. A. van Bodegraven, M. J. Pierik, Z. Mujagic

Summary: Abdominal pain is common in patients with IBD in remission and is associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Biochemistry & Molecular Biology

Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency

Debbie S. Deben, Luc J. J. Derijks, Bianca J. C. van den Bosch, Rob H. Creemers, Annick van Nunen, Adriaan A. van Bodegraven, Dennis R. Wong

Summary: This study aimed to evaluate the risks and opportunities of using tioguanine in inflammatory bowel disease (IBD) patients with abnormal TPMT metabolism and proposed preventative measures. The findings showed that a reduced dosage of tioguanine with strict monitoring was a safe and effective treatment option for IBD patients with dysfunctional TPMT.

METABOLITES (2023)

Meeting Abstract Gastroenterology & Hepatology

Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients

F. Van Moorsel, D. Deben, R. Creemers, B. Winkens, M. Pierik, P. Bus, M. Simsek, N. de Boer, A. van Bodegraven, D. Wong

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study

T. Van Rossen, K. van den Hoek, A. Budding, A. van Bodegraven

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study

T. Van Rossen, K. van den Hoek, A. Budding, A. van Bodegraven

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

IBD care from the patient perspective: The patient's turn

R. Creemers, D. van der Horst, I. Raats, M. Romberg-Camps, M. Scherpenzeel, A. van Bodegraven

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study

T. Straatmijer, M. Visschedijk, A. de Vries, F. Hoentjen, A. A. van Bodegraven, A. G. L. Bodelier, N. K. H. de Boer, G. Dijkstra, E. A. M. Festen, C. Horjus, J. M. Jansen, B. Jharap, W. Mares, B. Oldenburg, C. Y. Ponsioen, T. E. H. Romkens, N. Srivastava, M. M. van der Voorn, R. L. West, J. C. van der Woude, M. D. J. Wolvers, M. Pierik, A. E. van der Meulen, M. Duijvestein

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

A systematic review on outcome measures of long-term efficacy in clinical trials concerning Crohn's disease patients

L. Janssen, R. Creemers, A. van Bodegraven, M. Pierik

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study

R. Loveikyte, M. Boer, C. N. Van der Meulen, R. W. F. Ter Steege, G. Tack, J. Kuyvenhoven, B. Jharap, M. K. Vu, L. Vogelaar, R. L. West, S. Van der Marel, T. Romkens, Z. Mujagic, F. Hoentjen, A. A. Van Bodegraven, F. D. M. Van Schaik, A. C. De Vries, G. Dijkstra, A. E. Van der Meulen-De Jong

JOURNAL OF CROHNS & COLITIS (2022)

Meeting Abstract Gastroenterology & Hepatology

Chronic abdominal pain in IBD patients in remission: Real-world data on contributing factors

A. Rezazadeh Ardabili, L. M. Janssen, M. J. L. Romberg-Camps, D. Keszthelyi, D. M. A. E. Jonkers, A. A. van Bodegraven, M. J. Pierik, Z. Mujagic

JOURNAL OF CROHNS & COLITIS (2022)

No Data Available